​ Summary Globally, infection by seasonal influenza viruses causes 3–5 million cases of
severe illness and 290,000–650,000 respiratory deaths each year. Various influenza …

Vaccination is one of the most effective and cost-benefit interventions that prevent the
mortality and reduce morbidity from infectious pathogens. However, the licensed influenza …

Outbreaks of influenza A viruses continue to cause morbidity and mortality worldwide. The
global disease burden of influenza is substantial. While antiviral therapies are available …

Inactivated influenza vaccines are produced every year to fight against the seasonal
epidemics of influenza. Despite the nonoptimal coverage, even in subjects at risk like the …

Fears of a potential pandemic due to A (H5N1) viruses have focussed new attention on our
current vaccines, their shortcomings, and concerns regarding global vaccine supply in a …

Influenza viruses remain a severe burden to human health because of their contribution to
overall morbidity and mortality. Current seasonal influenza virus vaccines do not provide …

Influenza Vaccines for the Future | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Influenza vaccine preparations have been administered to humans since the late 1930s,
and the diversity of approaches in licensed trivalent seasonal or monovalent pandemic …

Despite seasonal influenza vaccines having been routinely used for many decades,
influenza A virus continues to pose a global threat to humans, causing high morbidity and …

Influenza virus causes an acute respiratory infection in humans. Frequent point mutations in
the influenza genome and occasional exchange of genetic segments between virus strains …